In this trial involving 264 hereditary angioedema attacks, oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
The New England Journal of Medicine: Search Results in Pulmonary/Critical Care
